NCT01158300

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Pediatric Brain Tumor Consortium · Network
• Sex: All
• Age: 3 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.

Detailed description

OBJECTIVES: Primary * To estimate the maximum-tolerated dose and the recommended phase II dose of VEGF inhibitor PTC299 (PTC299) in pediatric patients with recurrent or progressive primary central nervous system (CNS) tumors. * To evaluate and characterize the adverse events associated with this regimen in these patients. * To evaluate and characterize the pharmacokinetics and pharmacodynamics of this regimen in these patients. Secondary * To investigate the relationships between PTC299 plasma exposure and other outcomes measures. * To evaluate the antitumor activity of this regimen in these patients. * To evaluate changes in angiogenic and inflammatory markers in the blood and the relationship between these changes and other outcome measures. * To obtain preliminary evidence of biologic activity of PTC299 by using magnetic resonance diffusion to assess tumor cellularity. OUTLINE: This is a multicenter, dose-escalation study. Patients receive oral VEGF inhibitor PTC299 twice or thrice daily. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies by ELISA. After completion of study therapy, patients are followed up for 30 days.

Conditions

• Brain and Central Nervous System Tumors

Interventions

Type	Name	Description
DRUG	VEGF inhibitor PTC299	This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)

Timeline

• Start date: 2010-11-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2010-07-08
• Last updated: 2015-05-04

Locations

8 sites across 1 country: United States